Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze PTGX stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate PTGX investment potential.

What is PTGX stock price today?

Get real-time PTGX stock price, historical data, and price charts on Financhill. Track PTGX performance with our advanced analysis tools.

Is PTGX a good investment?

Evaluate PTGX investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy PTGX stock?

To buy PTGX stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of PTGX?

View detailed market capitalization data and company valuation metrics for PTGX on our comprehensive analysis page.

What is the P/E ratio of PTGX?

Use our fundamental analysis tools to view PTGX P/E ratio and compare valuation metrics with industry peers.

What are PTGX earnings?

View PTGX earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Protagonist Therapeutics, Inc. 10K Form

Buy

PTGX
Protagonist Therapeutics, Inc.

Last Price:

$87.33

Seasonality Move:

28.35%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-02	10Q	PTGX/Protagonist Therapeutics, Inc. Quarterly
2023-08-03	10Q	PTGX/Protagonist Therapeutics, Inc. Quarterly
2023-05-04	10Q	PTGX/Protagonist Therapeutics, Inc. Quarterly
2022-11-08	10Q	PTGX/Protagonist Therapeutics, Inc. Quarterly
2022-08-04	10Q	PTGX/Protagonist Therapeutics, Inc. Quarterly
2022-05-05	10Q	PTGX/Protagonist Therapeutics, Inc. Quarterly

Receive PTGX News And Ratings

See the #1 stock for the next 7 days that we like better than PTGX

PTGX Financial Statistics

Sales & Book Value

Annual Sales:	$434.4M
Cash Flow:	$-2M
Price / Cash Flow:	86.68
Annual Sales:	$10.34
Price / Book:	8.34

Profitability

EPS (TTM):	0.63330
Net Income (TTM):	$45.9M
Gross Margin:	$431.5M
Return on Equity:	7.15%
Return on Assets:	6.54%

Protagonist Therapeutics, Inc. Earnings Forecast

Key Protagonist Therapeutics, Inc. Financial Ratios

The Gross Profit Margin over the past 11 years for PTGX is 99.32%.
The Selling, General & Administrative Expenses for PTGX have been equal to 10.00% of Gross Profit Margin.
The Research & Development expenses have been 31.80% of Revenue.
The Interest Expense is 0.00% of Operating Income.
The Net Earning history of PTGX is 63.34% of Total Revenues.
Per Share Earnings over the last 11 years have been positive in 6 years.

Protagonist Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	PTGX
CUSIP:	74366E
Website:	protagonist-inc.com

Debt

Debt-to-Equity Ratio:	0.02
Current Ratio:	13.05
Quick Ratio:	12.83

Price-to-Earnings

Trailing P/E Ratio:	20.35
Forward P/E Ratio:	153.68

PTGX Technical Analysis vs Fundamental Analysis

Buy

Protagonist Therapeutics, Inc. (PTGX) is a Buy

Is Protagonist Therapeutics, Inc. a Buy or a Sell?

Protagonist Therapeutics, Inc. stock is rated a Buy

The current Protagonist Therapeutics, Inc. [PTGX] share price is $86.07. The Score for PTGX is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.